Home » EMA, U.S. FDA Back Biomarkers for Drug-Induced Kidney Injury
EMA, U.S. FDA Back Biomarkers for Drug-Induced Kidney Injury
December 16, 2014
The European Medicines Agency is lending support to an initiative to qualify biomarkers that can provide early warning of an investigational compound’s risks of causing drug-induced kidney injuries. Researchers have said the endorsement is necessary to move to the next phase of drug development.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor